Compare FRMI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRMI | TNGX |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | 137 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | 2025 | 2020 |
| Metric | FRMI | TNGX |
|---|---|---|
| Price | $5.97 | $24.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $26.13 | $21.78 |
| AVG Volume (30 Days) | ★ 18.9M | 2.0M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $120.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $4.47 | $6.25 |
| 52 Week High | $32.39 | $34.39 |
| Indicator | FRMI | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 45.55 |
| Support Level | $5.48 | $25.33 |
| Resistance Level | $7.41 | $25.76 |
| Average True Range (ATR) | 0.41 | 1.34 |
| MACD | -0.04 | -0.14 |
| Stochastic Oscillator | 14.32 | 35.47 |
Fermi Inc building a private power campus for AI-centric customers, developing and leasing large-scale, grid-independent energy generation and high-performance computing facilities purpose-built for the hyperscale era. The company is also developing a private energy and site infrastructure platform across the campus to support multiple powered shell buildings and a diversified, integrated power supply, including private power generation and delivery infrastructure, substations, internal distribution networks, water and cooling systems, and other essential infrastructure. In addition to powered shell facilities, it may offer long-term ground leases to tenants that elect to construct their own powered shell facilities on land, with or without integrated power delivery.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.